SOUTH SAN FRANCISCO, Calif. - IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25,.
SOUTH SAN FRANCISCO, Calif., April 26, 2024 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics,.
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial.
SOUTH SAN FRANCISCO, Calif., April 5, 2024 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today.